Transkaryotic down after Replagal panel

TKTX was down $2.25 (26%) to $6.49 on 7.2 million shares on Wednesday. On Tuesday, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted unanimously that the company has not provided s...